Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors
Authors:
Open Access
- 29 March 2019
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 9 (4) , 1-6
Abstract
No abstract availableFunding Information
- U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (R01 CA187299, R01 CA187299, R01 CA187299, R01 CA187299, R01 CA187299, R01 CA187299, R01 CA187299)
This publication has 15 references indexed in Scilit:
- Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphomaProceedings of the National Academy of Sciences, 2018
- Genetic and Functional Drivers of Diffuse Large B Cell LymphomaCell, 2017
- SGK12017
- B-Cell Receptor Signaling in Diffuse Large B-Cell lymphomaSeminars in Hematology, 2015
- MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphomaNature Immunology, 2013
- Development of a Small-Molecule Serum- and Glucocorticoid-Regulated Kinase-1 Antagonist and Its Evaluation as a Prostate Cancer TherapeuticCancer Research, 2008
- A novel N‐terminal hydrophobic motif mediates constitutive degradation of serum‐ and glucocorticoid‐induced kinase‐1 by the ubiquitin–proteasome pathwayThe FEBS Journal, 2006
- Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing AktCancer Research, 2004
- Rapid STAT Phosphorylation via the B Cell ReceptorJournal of Biological Chemistry, 1999
- Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum.Molecular and Cellular Biology, 1993